Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae , Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susc...
Cefaclor is administered orally. Adults -- The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled. Pediatric Patients -- The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours. In more serious infections, otitis media, and infections caused by less susceptibl...
www.fda.govRx Only
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor for Oral Suspension, USP, should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Cefaclor, USP, is a semisynthetic cephalosporin antibiotic for oral administration. It is chemically designated as 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate. The chemical formula for cefaclor is C15H14ClN3O4S•H2O and the molecular weight is 385.82.
After mixing, each 5 mL of Cefaclor for Oral Suspension will contain cefaclor monohydrate equivalent to 125 mg (0.34 mmol), 187 mg (0.51 mmol), 250 mg (0.68 mmol), or 375 mg (1.0 mmol) anhydrous cefaclor. The suspensions also contain methylcellulose, sodium lauryl sulfate, sucrose, and xanthan gum, FD&C Red No. 40, strawberry flavor.
The color of drug powder in the dry powder state is white to off-white. After reconstitution, it turns to a red suspension.
Cefaclor is well absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three fourths to 1 hour later. Following administration of 250 mg, 500 mg, and 1 g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL, respectively, were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations following the 250 mg, 500 mg and 1 g doses were approximately 600, 900 and 1,900 mcg/mL, respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%.
As with other cephalosporins, the bactericidal action of cefaclor results from inhibition of cell-wall synthesis.
Resistance to cefaclor is primarily through hydrolysis of beta-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. Pseudomonas spp., Acinetobacter calcoaceticus and most strains of Enterococci (Enterococcus faecalis, group D streptococci), Enterobacter spp., indole-positive Proteus, Morganella morganii (formerly Proteus morganii), Providencia rettgeri (formerly Proteus rettgeri), and Serratia spp. are resistant to cefaclor. Cefaclor is inactive against methicillin-resistant staphylococci. β-lactamase-negative, ampicillin-resistant strains of H. influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility to this agent.
Cefaclor has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
Gram-positive Bacteria
Staphylococcus aureus (methicillin susceptible only)
Coagulase negative staphylococci (methicillin susceptible only)
Streptococcus pneumoniae
Streptococcus pyogenes (group A β-hemolytic streptococci)
Gram-negative Bacteria
Escherichia coli
Haemophilus influenzae (excluding β-lactamase-negative, ampicillin-resistant strains)
Klebsiella spp.
Proteus mirabilis
The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoint of cefaclor. However, the safety and effectiveness of cefaclor in treating clinical infections due to these bacteria has not been established in adequate and well-controlled trials.
Gram-negative Bacteria
Citrobacter diversus
Moraxella catarrhalis
Neisseria gonorrhoeae
Anaerobic Bacteria
Bacteroides spp.
Peptococcus spp.
Peptostreptococcus spp.
Propionibacterium acnes
When available, the clinical microbiology laboratory should provide the result of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment.
Dilution Techniques
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized method (broth, agar, or microdilution)1,3. The MIC values should be interpreted according to criteria provided in Table 1.
Diffusion Techniques
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method2,3. This procedure uses paper disks impregnated with 30 mcg cefaclor to test the susceptibility of microorganisms to cefaclor. The disc diffusion interpretive criteria are provided in Table 1.
| 1 Susceptibility of staphylococci to cefaclor may be deduced from testing only penicillin and either cefoxitin or oxacillin 2 Susceptibility of Streptococcus pyogenes to cefaclor may also be deduced from testing penicillin | ||||||
| Microorganisms1,2 | Minimal Inhibitory Concentration (mcg/mL) | Zone Diameter (mm) | ||||
| S | I | R | S | I | R | |
| Streptococcus pneumoniae | ≤1 | 2 | ≥4 | -- | -- | -- |
A report of Susceptible indicates that antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the site of infection necessary to inhibit growth of the pathogen. A report of Intermediate indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.
Quality Control
Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2,3 Standard cefaclor powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg disk the criteria in Table 2 should be achieved.
| QC Strain | Minimal Inhibitory Concentration (mcg/mL) | Zone Diameter (mm) |
| Escherichia coli ATCC 25922 | 1 - 4 | 23 - 27 |
| Haemophilus influenzae ATCC 49766 | 1 - 4 | 25 - 31 |
| Staphylococcus aureus ATCC 25923 | -- | 27 - 31 |
| Staphylococcus aureus ATCC 29213 | 1 - 4 | -- |
| Streptococcus pneumoniae ATCC 49619 | 1 - 4 | 24 - 32 |
Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:
Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes
Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains.
Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes
Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains.
Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes
Note: Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present.
Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci
Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes
Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Cefaclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
BEFORE THERAPY WITH CEFACLOR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFACLOR, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.
IF AN ALLERGIC REACTION TO CEFACLOR OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.
Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefaclor for Oral Suspension, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Prescribing cefaclor in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increase the risk of the development of drug-resistant bacteria.
Prolonged use of cefaclor may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. It should be recognized that a positive Coombs' test may be due to the drug, e.g., in hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition.
Cefaclor should be administered with caution in the presence of markedly impaired renal function. Since the half-life of cefaclor in anuria is 2.3 to 2.8 hours, dosage adjustments for patients with moderate or severe renal impairment are usually not required. Clinical experience with cefaclor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.
As with other β-lactam antibiotics, the renal excretion of cefaclor is inhibited by probenecid.
Antibiotics, including cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Patients should be counseled that antibacterial drugs including Cefaclor for Oral Suspension should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefaclor for Oral Suspension is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping dose or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefaclor for Oral Suspension or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Patients receiving cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets.
There have been reports of increased anticoagulant effect when cefaclor and oral anticoagulants were administered concomitantly.
Studies have not been performed to determine potential for carcinogenicity, mutagenicity, or impairment of fertility.
Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no harm to the fetus due to cefaclor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
The effect of cefaclor on labor and delivery is unknown.
Small amounts of cefaclor have been detected in mother's milk following administration of single 500-mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/mL at 2, 3, 4, and 5 hours, respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefaclor is administered to a nursing woman.
Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.
Of the 3,703 patients in clinical studies of cefaclor, 594 (16.0%) were 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
This drug is known to be substantially excreted by the kidney (see CLINICAL PHARMACOLOGY), and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).
Adverse effects considered to be related to therapy with cefaclor are listed below:
Hypersensitivity reactions have been reported in about 1.5% of patients and include morbilliform eruptions (1 in 100). Pruritus, urticaria, and positive Coombs' tests each occur in less than 1 in 200 patients.
Cases of serum-sickness-like reactions have been reported with the use of cefaclor. These are characterized by findings of erythema multiforme, rashes, and other skin manifestations accompanied by arthritis/arthralgia, with or without fever, and differ from classic serum sickness in that there is infrequently associated lymphadenopathy and proteinuria, no circulating immune complexes, and no evidence to date of sequelae of the reaction. Occasionally, solitary symptoms may occur, but do not represent a serum-sickness-like reaction. While further investigation is ongoing, serum-sickness-like reactions appear to be due to hypersensitivity and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in pediatric patients than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) in overall clinical trials (with an incidence in pediatric patients in clinical trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in pediatric patients. Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported.
More severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely. Anaphylactoid events may be manifested by solitary symptoms, including angioedema, asthenia, edema (including face and limbs), dyspnea, paresthesias, syncope, hypotension, or vasodilatation. Anaphylaxis may be more common in patients with a history of penicillin allergy.
Rarely, hypersensitivity symptoms may persist for several months.
Gastrointestinal symptoms occur in about 2.5% of patients and include diarrhea (1 in 70).
Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS ). Nausea and vomiting have been reported rarely. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely.
Other effects considered related to therapy included eosinophilia (1 in 50 patients), genital pruritus, moniliasis or vaginitis (about 1 in 50 patients), and, rarely, thrombocytopenia or reversible interstitial nephritis.
Causal Relationship Uncertain --
CNS -- Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, and somnolence have been reported.
Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.
Hepatic -- Slight elevations of AST, ALT, or alkaline phosphatase values (1 in 40).
Hematopoietic -- As has also been reported with other β-lactam antibiotics, transient lymphocytosis, leukopenia, and, rarely, hemolytic anemia, aplastic anemia, agranulocytosis, and reversible neutropenia of possible clinical significance.
There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and Coumadin® concomitantly.
Renal -- Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).
In addition to the adverse reactions listed above that have been observed in patients treated with cefaclor, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: fever, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, hemorrhage, false-positive test for urinary glucose, elevated bilirubin, elevated LDH, and pancytopenia.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (see DOSAGE AND ADMINISTRATION and OVERDOSAGE sections).
To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or www.fda.gov.
Signs and Symptoms -- The toxic symptoms following an overdose of cefaclor may include nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose-related. If other symptoms are present, it is probable that they are secondary to an underlying disease state, an allergic reaction, or the effects of other intoxication.
Treatment -- To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians' Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal decontamination will not be necessary.
Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.
Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cefaclor.
Cefaclor is administered orally.
Adults -- The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
Pediatric Patients -- The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours. In more serious infections, otitis media, and infections caused by less susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage of 1 g/day.
| Cefaclor for Oral Suspension, USP | ||
| 20 mg/kg/day | ||
| Weight | 125 mg/5 mL | 250 mg/5 mL |
| 9 kg | 1/2 tsp t.i.d. | |
| 18 kg | 1 tsp t.i.d. | 1/2 tsp t.i.d. |
| 40 mg/kg/day | ||
| 9 kg | 1 tsp t.i.d. | 1/2 tsp t.i.d. |
| 18 kg | 1 tsp t.i.d. | |
B.I.D. Treatment Option —For the treatment of otitis media and pharyngitis, the total daily dosage may be divided and administered every 12 hours.
| Cefaclor for Oral Suspension, USP | ||
| 20 mg/kg/day (Pharyngitis) | ||
| Weight | 187 mg/5 mL | 375 mg/5 mL |
| 9 kg | 1/2 tsp b.i.d. | |
| 18 kg | 1 tsp b.i.d. | 1/2 tsp b.i.d. |
| 40 mg/kg/day (Otitis Media) | ||
| 9 kg | 1 tsp b.i.d. | 1/2 tsp b.i.d. |
| 18 kg | 1 tsp b.i.d. | |
Cefaclor may be administered in the presence of impaired renal function. Under such a condition, the dosage usually is unchanged (see PRECAUTIONS).
In the treatment of β-hemolytic streptococcal infections, a therapeutic dosage of cefaclor should be administered for at least 10 days.
Add appropriate water volume as indicated in the following table in two portions to dry mixture in the bottle. Shake well after each addition.
Each 5 mL (approximately one teaspoonful) will then contain Cefaclor, USP, monohydrate equivalent to 125 mg, 187 mg, 250 mg or 375 mg anhydrous cefaclor, respectively, as shown in the following table.
Oversize bottle provides extra space for shaking.
| Cefaclor For Oral Suspension, USP | ||
|---|---|---|
| Strength Package Size (when mixed) | Water Volume to Add | Anhydrous Cefaclor/5 mL (approx. one teaspoonful) |
| 125 mg/5 mL | ||
| 75 mL | 53 mL | 125 mg |
| 150 mL | 106 mL | |
| 187 mg/5 mL | ||
| 50 mL | 35 mL | 187 mg |
| 100 mL | 70 mL | |
| 250 mg/5 mL | ||
| 75 mL | 53 mL | 250 mg |
| 150 mL | 106 mL | |
| 375 mg/5 mL | ||
| 50 mL | 34 mL | 375 mg |
| 100 mL | 68 mL | |
Cefaclor Oral Suspension, USP, is supplied in bottles with child-resistant caps as:
125 mg/5 mL strawberry flavor:
NDC 61442-173-02 (75-mL size)
NDC 61442-173-01 (150-mL size)
187 mg/5 mL strawberry flavor
NDC 61442-174-02 (50-mL size)
NDC 61442-174-01 (100-mL size)
250 mg/5 mL strawberry flavor
NDC 61442-175-02 (75-mL size)
NDC 61442-175-01 (150-mL size)
375 mg/5 mL strawberry flavor
NDC 61442-176-02 (50-mL size)
NDC 61442-176-01 (100-mL size)
After mixing, store in a refrigerator. Shake well before using. Keep tightly closed. The mixture may be kept for 14 days without significant loss of potency. Discard unused portion after 14 days.
Store dry powder at 20∘to 25℃ (68∘to 77℉). [See USP Controlled Room Temperature].
Manufactured by:Yung Shin Pharmaceutical Ind. Co., Ltd.
Tachia, Taichung 43769
TAIWAN
Distributed by:Carlsbad Technology, Inc.,
5923 Balfour Court,
Carlsbad, CA 92008, U.S.A
Revised: 09/15
NDC 61442-173-02
CEFACLOR
For Oral Suspension, USP
125 mg per 5 mL
75 mL (when mixed)
SHAKE WELL BEFORE USE
Rx
Only
Carlsbad Technology, Inc.
NDC 61442-173-01
CEFACLOR
For Oral Suspension, USP
125 mg per 5 mL
150 mL (when mixed)
SHAKE WELL BEFORE USE
Rx Only
Carlsbad Technology, Inc.
NDC 61442-174-02
CEFACLOR
For Oral Suspension, USP
187 mg per 5 mL
50 mL (when mixed)
SHAKE WELL BEFORE USE
Rx Only
Carlsbad Technology, Inc.
NDC 61442-174-01
CEFACLORFor Oral Suspension, USP
187 mg per 5 mL
100 mL (when mixed)
SHAKE WELL BEFORE USE
Rx Only
Carlsbad Technology, Inc.
NDC 61442-175-02
CEFACLOR
For Oral Suspension, USP
250 mg per 5 mL
75 mL (when mixed)
SHAKE WELL BEFORE USE
Rx
Only
Carlsbad Technology, Inc.
NDC 61442-175-01
CEFACLOR
For Oral Suspension, USP
250 mg per 5 mL
150 mL (when mixed)
SHAKE WELL BEFORE USE
Rx Only
Carlsbad Technology, Inc.
NDC 61442-176-02
CEFACLOR
For Oral Suspension, USP
375 mg per 5 mL
50 mL (when mixed)
SHAKE WELL BEFORE USE
Rx Only
Carlsbad Technology, Inc.
NDC 61442-176-01
CEFACLOR
For Oral Suspension, USP
375 mg per 5 mL
100 mL (when mixed)
SHAKE WELL BEFORE USE
Rx Only
Carlsbad Technology, Inc.
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 61442-173-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-173-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-174-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-174-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-175-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-175-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-176-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| 61442-176-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4ef4-f424-e053-dadaa90a57ce | Cefaclor for Oral Suspension, USP |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 61442-173 | CEFACLOR SUSPENSION [CARLSBAD TECHNOLOGY, INC.] | 3 | Legacy NDC | 20151021_9f919252-7a87-4386-a64c-5d8213f7e881.zip |
| 61442-174 | CEFACLOR SUSPENSION [CARLSBAD TECHNOLOGY, INC.] | 3 | Legacy NDC | 20151021_9f919252-7a87-4386-a64c-5d8213f7e881.zip |
| 61442-175 | CEFACLOR SUSPENSION [CARLSBAD TECHNOLOGY, INC.] | 3 | Legacy NDC | 20151021_9f919252-7a87-4386-a64c-5d8213f7e881.zip |
| 61442-176 | CEFACLOR SUSPENSION [CARLSBAD TECHNOLOGY, INC.] | 3 | Legacy NDC | 20151021_9f919252-7a87-4386-a64c-5d8213f7e881.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Cefaclor | ACTIVE INGREDIENT | 69K7K19H4L | 3 | |
| Cefaclor Anhydrous | ACTIVE MOIETY | 3Z6FS3IK0K | 3 | |
| FD&C Red No. 40 | INACTIVE INGREDIENT | WZB9127XOA | 3 | |
| METHYLCELLULOSE (25 CPS) | INACTIVE INGREDIENT | BI55GG2WLI | 3 | |
| sodium lauryl sulfate | INACTIVE INGREDIENT | 368GB5141J | 3 | |
| sucrose | INACTIVE INGREDIENT | C151H8M554 | 3 | |
| xanthan gum | INACTIVE INGREDIENT | TTV12P4NEE | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 61442-173 | 61442-173-02, 61442-173-01 |
| 61442-174 | 61442-174-02, 61442-174-01 |
| 61442-175 | 61442-175-02, 61442-175-01 |
| 61442-176 | 61442-176-02, 61442-176-01 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | SOLUTION / DENTAL | NA | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / SUBLINGUAL | 1.1 mg | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET, FILM COATED / ORAL | 2.5 mg | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | ELIXIR / ORAL | 12.5 mg/5ml | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | DROPS / ORAL | NA | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | SUSPENSION / ORAL | 360 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | POWDER / RESPIRATORY (INHALATION) | NA | ||
| sucrose | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | POWDER, FOR SOLUTION / ORAL | 0.33 mg/5ml | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, COATED / ORAL | 123 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | SUSPENSION / ORAL | 705 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | INSERT / VAGINAL | 15 mg | ||
| sucrose | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | SPONGE / TOPICAL | NA | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, FOR SUSPENSION / ORAL | 264 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, EFFERVESCENT / ORAL | 1.5 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | SPRAY / TOPICAL | 7 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TROCHE / ORAL | 948 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET, EXTENDED RELEASE / ORAL | 528 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | GEL / VAGINAL | 0.2 %w/w | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET, FILM COATED / ORAL | 0.08 mg | ||
| sucrose | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| sucrose | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, COATED / ORAL | NA | ||
| sucrose | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET, EXTENDED RELEASE / ORAL | 2.22 mg | ||
| sucrose | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | POWDER, FOR SUSPENSION / ORAL | 64 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | SUSPENSION/ DROPS / ORAL | 22 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | SUSPENSION, EXTENDED RELEASE / ORAL | 0.08 mg/1ml | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET / ORAL | 56 mg | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, COATED PELLETS / ORAL | NA | ||
| FD&C Red No. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET / SUBLINGUAL | NA | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | FILM, SOLUBLE / ORAL | 1 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 36 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | ENEMA / RECTAL | 150 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, ORALLY DISINTEGRATING / ORAL | 16 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | PASTE / ORAL | 1050 mg | ||
| sucrose | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, FILM COATED / ORAL | 240 mg | ||
| sucrose | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | CAPSULE, DELAYED RELEASE / ORAL | 46 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | SUSPENSION / TOPICAL | 0.11 %w/v | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 2350 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | CREAM / VAGINAL | 12 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | CAPSULE / ORAL | 600 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION / ORAL | 450 mg | ||
| sucrose | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | CREAM / TOPICAL | 214 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | GEL / DENTAL | 1.47 %w/w | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING / ORAL | 0.15 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A065412-001 | CEFACLOR | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | ||
| A065412-002 | CEFACLOR | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | ||
| A065412-003 | CEFACLOR | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | ||
| A065412-004 | CEFACLOR | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065412-001 | CEFACLOR | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065412-002 | CEFACLOR | EQ 187MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065412-003 | CEFACLOR | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2012-02-17 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065412-004 | CEFACLOR | EQ 375MG BASE/5ML | FOR SUSPENSION / ORAL | RS | 2012-02-17 | 5bbf6a4d5a75… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 49db0885-5ac9-fd11-e063-6394a90a381f | 9f919252-7a87-4386-a64c-5d8213f7e881 | 2026-02-02 | Warnings, Adverse reactions | 9f919252-7a87-4386-a64c-5d8213f7e881 |
Adverse event summaries are temporarily unavailable. Other product information remains available.